维奈克拉联合低甲基化药物用于新诊断急性髓系白血病危重症患者
本回顾性分析纳入16例新诊断急性髓系白血病并入住重症监护室接受维奈克拉联合低甲基化药物治疗的危重症患者,其中13例为原发急性髓系白血病、3例为骨髓增生异常综合征转化急性髓系白血病。首个疗程后12例(75%)达完全缓解或伴血液学不完全恢复的完全缓解,中位随访9.5个月(范围0.5-23)时总生存率为43.75%。
要点
- 危重症新诊断急性髓系白血病患者接受维奈克拉联合低甲基化药物,首个疗程后75%达完全缓解或伴血液学不完全恢复的完全缓解。
- 全部患者均发生3-4级血液学不良事件。
- 中位随访9.5个月时总生存率为43.75%。
核心结论
- 维奈克拉联合低甲基化药物在新诊断急性髓系白血病危重症患者中显示出显著提高的治疗反应率。
- TP53野生型患者及首个维奈克拉联合低甲基化药物疗程后达完全缓解状态提示生存更优。
研究设计与样本
- 回顾性分析,纳入16例新诊断急性髓系白血病并入住重症监护室接受维奈克拉联合低甲基化药物治疗的危重症患者。
- 其中13例为原发急性髓系白血病,3例为骨髓增生异常综合征转化急性髓系白血病。
- 平均急性生理与慢性健康评估II(APACHE II)评分为18.9,平均脓毒症相关器官衰竭评估(SOFA)评分为6.2。
主要发现
- 重症监护室平均住院时间为27.3天,维奈克拉给药中位持续时间为16天。
- 首个维奈克拉联合低甲基化药物疗程后,12例(75%)达完全缓解或伴血液学不完全恢复的完全缓解。
- 5例携带TP53突变患者中总缓解率为90%。
- 全部患者均发生3-4级血液学不良事件。
- 中位随访9.5个月(范围0.5-23)时总生存率为43.75%。
局限性
- 原文结论提及该联合方案在新诊断急性髓系白血病危重症患者中显示出显著提高的治疗反应率,未报告其他局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Venetoclax (VEN) in combination with hypomethylating agents (HMAs) is considered the standard of treatment for individuals with newly diagnosed acute myeloid leukaemia (AML) who are ineligible for intensive chemotherapy. We conducted a retrospective analysis that encompassed 16 critically ill patients newly diagnosed with AML who were admitted to the intensive care unit (ICU) and received the VEN and HMA regimen. Among them, 13 were primary AML, and three were MDS-transformed AML. The mean Acute Physiology and Chronic Health Evaluation II (APACHE II) score was 18.9, and the mean sepsis-related organ failure assessment score (SOFA) was 6.2. The average length of the ICU stay was 27.3 days. The median duration of VEN administration was 16 days. After the first course of VEN + HMA, 12 cases (75%) achieved complete remission (CR) or CR with incomplete haematological recovery (CRi). Among the five patients harbouring TP53 mutations, the overall response rate (ORR) was 90%. All patients experienced grade 3-4 haematological adverse events (AEs). With a median follow-up of 9.5 months (range: 0.5-23), the overall survival (OS) rate was 43.75%. TP53-wild patients and CR state after the first course of VEN-HMA indicated better survival. The combination of VEN and HMA has demonstrated a significantly elevated therapeutic response rate in newly diagnosed AML patients with critical illness.
引用
- Liang P, Xie Y, Liu Z, et al. Venetoclax and hypomethylating agents in critically ill patients with newly diagnosed acute myeloid leukaemia. Br J Haematol. 2024. PMID: 38180132. doi:10.1111/bjh.19291
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。